Comparative Pharmacology
Head-to-head clinical analysis: MIVACURIUM CHLORIDE versus NORCURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACURIUM CHLORIDE versus NORCURON.
MIVACURIUM CHLORIDE vs NORCURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mivacurium chloride is a non-depolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor end-plate, preventing acetylcholine from binding and thereby inhibiting neuromuscular transmission. It is a mixture of stereoisomers and is rapidly hydrolyzed by plasma cholinesterase.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and inducing skeletal muscle paralysis.
0.15-0.25 mg/kg IV bolus for endotracheal intubation; maintenance infusion: 0.5-1.5 mcg/kg/min IV
0.08-0.1 mg/kg IV bolus for intubation; maintenance 0.01-0.015 mg/kg IV every 30-60 min as needed or continuous infusion at 0.06-0.12 mg/kg/hr.
None Documented
None Documented
Terminal elimination half-life is approximately 2 minutes (range 1-3 minutes) for the initial rapid distribution phase, and the elimination half-life is about 17-20 minutes in patients with normal renal function. Clinically, this short half-life allows for rapid recovery of neuromuscular function.
Terminal elimination half-life is approximately 1.3-2.2 hours in adults; prolonged in hepatic or renal impairment (up to 3-4 hours in renal failure).
Primarily renal excretion of unchanged drug and metabolites; approximately 90-95% eliminated via urine, with less than 5% in feces. Minor biliary excretion.
Approximately 40-50% of the dose is excreted unchanged in urine within 24 hours; 20-30% is eliminated in feces as unchanged drug and metabolites; minor biliary excretion.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker